Biotech Acquisition Co (Biotech Acquisition Co) Cash And Cash Equivalents : $0.01 Mil (As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Biotech Acquisition Co Cash And Cash Equivalents?

Biotech Acquisition Co's quarterly cash and cash equivalents declined from Mar. 2022 ($0.10 Mil) to Jun. 2022 ($0.00 Mil) but then increased from Jun. 2022 ($0.00 Mil) to Sep. 2022 ($0.01 Mil).

Biotech Acquisition Co's annual cash and cash equivalents stayed the same from . 20 ($0.00 Mil) to Dec. 2020 ($0.00 Mil) but then increased from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($0.09 Mil).

Biotech Acquisition Co Cash And Cash Equivalents Historical Data

The historical data trend for Biotech Acquisition Co's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotech Acquisition Co Cash And Cash Equivalents Chart

Biotech Acquisition Co Annual Data

Trend

Dec20

Dec21

Cash And Cash Equivalents

0.09

Biotech Acquisition Co Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Cash And Cash Equivalents	Get a 7-Day Free Trial				0.40	0.09	0.10	-	0.01

Biotech Acquisition Co Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Biotech Acquisition Co (NAS:BIOT) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Biotech Acquisition Co Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Biotech Acquisition Co's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Biotech Acquisition Co (Biotech Acquisition Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Biotech Acquisition Co (NAS:BIOT) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

545 West 25th Street, 20th Floor, New York, NY, USA, 10001

Website

Biotech Acquisition Co is a blank check company.

Executives

Albert F Hummel	director, officer: Chief Investment Officer	PO BOX 3407, RANCHO SANTA FE CA 92067
Biotech Sponsor Llc	10 percent owner	545 W. 25TH ST., 20TH FLOOR, NEW YORK NY 10001
Bruno Montanari	director	545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001
Ivan Jarry	officer: Chief Operating Officer	545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001
Paul Bernard	director	545 WEST 25TH STREET 20TH FL, NEW YORK NY 10001
Aaron Kim	director	545 WEST 25TH STREET 20TH FL, NEW YORK NY 10001
Michael Schleifer	director, 10 percent owner, officer: Chief Executive Officer	545 WEST 25TH STREET 20TH FLOOR, NEW YORK NY 10001
Thomas Fratacci	officer: CFO & Treasurer	545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001